Last updated on February 2018

Immune Disorder HSCT Protocol

Brief description of study

This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders. A regimen that maximizes host immune suppression is expected to reduce graft rejection and optimize donor cell engraftment.

Clinical Study Identifier: NCT01821781

Contact Investigators or Research Sites near you

Start Over

Jeffrey Bednarski, MD

Washington University
Saint Louis, MO United States
  Connect »

Troy Quigg, DO, MS

Methodist Heathcare
San Antonio, TX United States
  Connect »